Enzyvant expects its BLA for a tissue-based regenerative therapy to be reviewed and potentially approved in 2019, so solving the reimbursement issue is urgent for both the company and for patients.
New, cross-border investments trigger federal scrutiny via CFIUS when emerging biotech technology is involved.
The value of China’s biotechs fell some 30 percent since the trade war began, and VC funding, while strong, slipped before that. Interest in China, however, remains strong.
The value of China’s biotechs fell some 30 percent since the trade war began, and VC funding, while strong, slipped before that. Interest in China, however, remains strong.
Foghorn Therapeutics is managing to sidestep some of the growing pains common to early companies, thanks to its genesis as a VC-founded company.
IP theft seems inevitable when pharma companies enter regions with weak IP. That risk is reduced, however, when companies spread their activities throughout the region rather than centralizing them in one country.
When Viela Bio spun out of MedImmune last spring, it started with some assets well into development. Now it’s focusing on speed and continuity as it advances those assets through the clinic.
With a hypercompetitive landscape and growing demands for real world data, companies need a comprehensive, cross-silo, data strategy to uncover unobvious insights and develop new data streams.
Pharmas have a decision to make: Are they drug developers, or are they healthcare companies? Whatever the answer, the proliferation of innovative digital solutions is triggering the need for new business models tailored to what companies want to become, rather than what they’ve always been.
Tax reform means more cash on hand, but major changes for R&D expensing, net operating losses, and executive compensation.
